

ASX Announcement

Medibio Limited – 19 January 2018



Resignation of Director

Sydney, Australia and Minneapolis, MN – 19 January 2018: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCQB: MDBIF) announces that Dr. Adam Darkins has resigned from the Board of Directors of Medibio due to time constraints as he focuses on his growing consulting practice and a desire to write a new book. Medibio will continue to utilise Dr. Darkins as a consultant and thanks him for his many contributions to the company's growth.

About Medibio Limited

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective biometrics to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au.

– ENDS –

Further Information:		Website: www.medibio.com.au	
Medibio Shareholder Enquiries: Stephanie Ottens Investor Relations Director Medibio Limited stephanie.ottens@medibio.com.au T: +61 434 405 400		Australian Media Enquiries: Peter Taylor NWR Communications peter@nwrcommunications.com.au T: +61 (0) 412 036 231	